When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
AVRO - Dosing underway in Avrobio's gaucher disease and cystinosis trials
AVROBIO Inc.
Avrobio (NASDAQ:AVRO) doses first patient in its Phase 1/2 GuardOne clinical trial, evaluating AVR-RD-02 for Gaucher disease type 1, an inherited disorder caused by the accumulation of a type of lipid in tissues due to the dysfunction in a certain enzyme.
More news on: AVROBIO, Inc., Healthcare stocks news,